Ipsen’s sales grow 2.2% in 2013, but miss expectations

28 January 2014

French drugmaker Ipsen (Euronext: IPN) posted solid sales growth for fourth-quarter and full-year 2013, though there was a significant slowdown on the domestic market. The company did not release profit figures at this stage.

Group sales for the full-year came in at 1.22 billion euros ($1.68 billion), up 2.2% at constant currency, but fell short of average expectations of analysts polled by Reuters for revenue of 1.26 billion euros. Sales were 293.0 million euros for the fourth quarter, a rise of 2.0% at cc. Sales of Specialty care products advanced 3.0% to 871.1 million for the year and rose 2.6% to 209.9 million for the quarter. Primary care products dipped 0.1% to 320.2 million euros and rose 2.0% to 77.5 million for the quarter.

In the Speciality care sector, Ipsen’s biggest selling product was Decapeptyl (triptorelin), which generated 298.6 million, down 1.9%, and Somatuline (lanreotide) sales leapt 11.1% to 246.9 million euros for the full year. Dysport (abobotulinumtoxinA) turnover grew 7% to 242.2 million euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK